← Leaderboards
David H Perlmutter
Washington University
$25,711,247
Attributed
$26,920,940
Total exposure
24
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,960,176 · 27
By mechanism
P01$23,695,037 · 5
R01$14,062,032 · 7
M01$3,127,090 · 3
K12$3,102,154 · 1
T32$1,776,511 · 3
C06$1,250,000 · 1
Top collaborators
- David A Rudnick4 shared
Most similar at Washington University
Same institution · by research overlap
- Brian Jesse Debosch$7,536,271
- Makedonka Mitreva$12,990,587
- James W Janetka$9,104,937
- Luis Francisco Zirnberger Batista$6,227,466
- David A Rudnick$3,126,164
Others in their field
Top investigators on “Endoplasmic Reticulum”
- Randal J. Kaufman · Indiana University Indianapolis$33,249,957
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Peter Arvan · University Of Michigan At Ann Arbor$23,625,830
- Feroz R Papa · University Of California San Francisco$18,595,073
- Zihai Li · Ohio State University$17,028,405
- J. Kevin Kevin Foskett · University Of Pennsylvania$16,942,170
Research focus
Endoplasmic ReticulumMouse ModelCell LineLiver DiseasesHepatocyteGeneticHepaticMutantLiverPharmaceutical PreparationsPathway InteractionsAutophagocytosisCellsBiological ModelsLiver TransplantationPhenotypeLiver FibrosisPrimary Carcinoma Of The Liver CellsCaenorhabditis ElegansBaseProteinsSignal PathwayIn VivoCarbamazepine
Grant awards (104)
Novel therapies that target mitochondrial dysfunction for treatment of a1-antitrypsin deficiency liver disease$548,069
R01 · FY2025 · DK
Novel therapies that target mitochondrial dysfunction for treatment of a1-antitrypsin deficiency liver disease$584,605
R01 · FY2024 · DK
New Therapies for Liver Fibrosis and Hyperproliferation in Alpha1-AT Deficiency$1,848,657
P01 · FY2023 · DK · contact PI
Novel therapies that target mitochondrial dysfunction for treatment of a1-antitrypsin deficiency liver disease$623,637
R01 · FY2023 · DK
Treating AT Deficiency with Drugs that Modulate the Proteostasis Network$402,011
P01 · FY2023 · DK · contact PI
New Therapies for Liver Fibrosis and Hyperproliferation in Alpha1-AT Deficiency$1,876,851
P01 · FY2022 · DK · contact PI
Novel therapies that target mitochondrial dysfunction for treatment of a1-antitrypsin deficiency liver disease$663,075
R01 · FY2022 · DK
Treating AT Deficiency with Drugs that Modulate the Proteostasis Network$410,382
P01 · FY2022 · DK · contact PI
New Therapies for Liver Fibrosis and Hyperproliferation in Alpha1-AT Deficiency$1,905,228
P01 · FY2021 · DK · contact PI
Treating AT Deficiency with Drugs that Modulate the Proteostasis Network$417,961
P01 · FY2021 · DK · contact PI
New Therapies for Liver Fibrosis and Hyperproliferation in Alpha1-AT Deficiency$1,925,515
P01 · FY2020 · DK · contact PI
Treating AT Deficiency with Drugs that Modulate the Proteostasis Network$422,333
P01 · FY2020 · DK · contact PI
New Therapies for Liver Fibrosis and Hyperproliferation in Alpha1-AT Deficiency$1,988,500
P01 · FY2019 · DK · contact PI
Treating AT Deficiency with Drugs that Modulate the Proteostasis Network$436,500
P01 · FY2019 · DK · contact PI
Signaling Pathways Influencing Liver Disease Phenotype in Antitrypsin Deficiency$452,417
R01 · FY2017 · DK · contact PI
New therapies for liver fibrosis and hyperproliferation in alpha1-AT deficiency$1,479,015
P01 · FY2016 · DK · contact PI
Signaling Pathways Influencing Liver Disease Phenotype in Antitrypsin Deficiency$460,770
R01 · FY2016 · DK · contact PI
New therapies for liver fibrosis and hyperproliferation in alpha1-AT deficiency$1,803,138
P01 · FY2015 · DK · contact PI
Signaling pathways influencing liver disease phenotype in antitrypsin deficiency$460,367
R01 · FY2015 · DK · contact PI
Molecular Basis of Pediatric Disease$432,000
K12 · FY2015 · HD · contact PI
Treating AT deficiency with drugs that modulate the proteoatasis network$352,533
P01 · FY2015 · DK · contact PI
New therapies for liver fibrosis and hyperproliferation in alpha1-AT deficiency$1,833,329
P01 · FY2014 · DK · contact PI
Signaling pathways influencing liver disease phenotype in antitrypsin deficiency$455,514
R01 · FY2014 · DK · contact PI
Molecular Basis of Pediatric Disease$432,000
K12 · FY2014 · HD · contact PI
Treating AT deficiency with drugs that modulate the proteoatasis network$360,421
P01 · FY2014 · DK · contact PI
Basic/Translational Research Training for CHP Pediatric Fellows$350,058
T32 · FY2014 · HD · contact PI
New therapies for liver fibrosis and hyperproliferation in alpha1-AT deficiency$1,786,840
P01 · FY2013 · DK · contact PI
Treating AT deficiency with drugs that modulate the proteoatasis network$355,830
P01 · FY2013 · DK · contact PI
Molecular Basis of Pediatric Disease$316,566
K12 · FY2013 · HD · contact PI
Basic/Translational Research Training for CHP Pediatric Fellows$202,119
T32 · FY2013 · HD · contact PI
New therapies for liver fibrosis and hyperproliferation in alpha1-AT deficiency$1,894,047
P01 · FY2012 · DK · contact PI
Hepatocellular Carcinoma in Antitrypsin Deficiency$419,691
R01 · FY2012 · DK · contact PI
Novel Pharmacological Strategies for Liver Disease in Antitrypsin Deficiency$359,319
R01 · FY2012 · DK · contact PI
Treating AT deficiency with drugs that modulate the proteoatasis network$270,579
P01 · FY2012 · DK · contact PI
Molecular Basis of Pediatric Disease$260,289
K12 · FY2012 · HD · contact PI
Carbamazepine for severe liver disease due to antitrypsin deficiency$227,250
R21 · FY2012 · DK · contact PI
Therapeutic Use of Autophagy Enhancer Drugs for Alzheimer's Disease$160,969
R21 · FY2012 · AG · contact PI
Hepatocellular Carcinoma in Antitrypsin Deficiency$419,691
R01 · FY2011 · DK · contact PI
Novel Pharmacological Strategies for Liver Disease in Antitrypsin Deficiency$378,194
R01 · FY2011 · DK · contact PI
Molecular Basis of Pediatric Disease$196,724
K12 · FY2011 · HD · contact PI
Therapeutic Use of Autophagy Enhancer Drugs for Alzheimer's Disease$193,163
R21 · FY2011 · AG · contact PI
Carbamazepine for severe liver disease due to antitrypsin deficiency$189,375
R21 · FY2011 · DK · contact PI
Hepatocellular Carcinoma in Antitrypsin Deficiency$427,556
R01 · FY2010 · DK · contact PI
Novel Pharmacological Strategies for Liver Disease in Antitrypsin Deficiency$405,247
R01 · FY2010 · DK · contact PI
Molecular Basis of Pediatric Disease$316,557
K12 · FY2010 · HD · contact PI
Novel Pharmacological Strategies for Liver Disease in Antitrypsin Deficiency$437,522
R01 · FY2009 · DK · contact PI
Hepatocellular Carcinoma in Antitrypsin Deficiency$422,959
R01 · FY2009 · DK · contact PI
Hepatocellular Carcinoma in Antitrypsin Deficiency$412,251
R01 · FY2008 · DK · contact PI
Molecular Basis of Pediatric Disease$383,646
K12 · FY2008 · HD · contact PI
Molecular Basis of Pediatric Disease$382,662
K12 · FY2008 · HD · contact PI
Local Expression of Alpha-1-Antitrypsin in Emphysema$340,160
R01 · FY2008 · HL · contact PI
Molecular Basis of Pediatric Disease$381,710
K12 · FY2007 · HD · contact PI
Liver Injury in Alpha-1-Antitrypsin Deficiency$349,850
R01 · FY2007 · DK · contact PI
Local Expression of Alpha-1-Antitrypsin in Emphysema$340,160
R01 · FY2007 · HL · contact PI
General Clinical Research Center$394,946
M01 · FY2006 · RR · contact PI
Liver Injury in Alpha-1-Antitrypsin Deficiency$351,760
R01 · FY2006 · DK · contact PI
Local Expression of Alpha-1-Antitrypsin in Emphysema$350,319
R01 · FY2006 · HL · contact PI
Biliary Atresia Clinical Research Consortium: Pittsburgh$233,935
U01 · FY2006 · DK · contact PI
The Clinical Interface of Molecular and Cellular Biology$219,682
T32 · FY2006 · HD · contact PI
Screening for Genetic Mechanisms for Biliary Atresia$140,128
R03 · FY2006 · DK · contact PI
General Clinical Research Center$1,079,926
M01 · FY2005 · RR
Local Expression of Alpha-1-Antitrypsin in Emphysema$358,750
R01 · FY2005 · HL
Liver Injury in Alpha-1-Antitrypsin Deficiency$350,282
R01 · FY2005 · DK
Biliary Atresia Clinical Research Consortium: Pittsburgh$238,710
U01 · FY2005 · DK
The Clinical Interface of Molecular and Cellular Biology$193,521
T32 · FY2005 · HD
Screening for Genetic Mechanisms for Biliary Atresia$143,500
R03 · FY2005 · DK
A PROSPECTIVE DATABASE OF INFANTS WITH CHOLESTASIS$3,189
M01 · FY2005 · RR
GENERAL CLINICAL RESEARCH CENTER$819,340
M01 · FY2004 · RR
Local Expression of Alpha-1-Antitrypsin in Emphysema$358,750
R01 · FY2004 · HL
Liver Injury in Alpha-1-Antitrypsin Deficiency$340,345
R01 · FY2004 · DK
ER RETENTION IN ALPHA-1-ANTITRYPSIN LIVER DISEASE$273,438
R01 · FY2004 · DK
Biliary Atresia Clinical Research Consortium: Pittsburgh$238,710
U01 · FY2004 · DK
The Clinical Interface of Molecular and Cellular Biology$226,641
T32 · FY2004 · HD
GENERAL CLINICAL RESEARCH CENTER$829,689
M01 · FY2003 · RR
Liver Injury in Alpha-1-Antitrypsin Deficiency$329,861
R01 · FY2003 · DK
LOCAL EXPRESSION OF ALPHA-1-ANTITRYPSIN IN EMPHYSEMA$280,000
R01 · FY2003 · HL
ER RETENTION IN ALPHA-1-ANTITRYPSIN LIVER DISEASE$266,692
R01 · FY2003 · DK
The Clinical Interface of Molecular and Cellular Biology$224,864
T32 · FY2003 · HD
Biliary Atresia Clinical Research Consortium: Pittsburgh$168,462
U01 · FY2003 · DK
LOCAL EXPRESSION OF ALPHA-1-ANTITRYPSIN IN EMPHYSEMA$280,000
R01 · FY2002 · HL
ER RETENTION IN ALPHA-1-ANTITRYPSIN LIVER DISEASE$260,141
R01 · FY2002 · DK
The Clinical Interface of Molecular and Cellular Biology$216,984
T32 · FY2002 · HD
Core--Cell biology$180,000
P30 · FY2002 · DK
Biliary Atresia Clinical Research Consortium: Pittsburgh$168,462
U01 · FY2002 · DK
ALPHA 1 ANTITRYPSIN DEFICIENCY--GENOTYPE/PHENOTYPE STUDIES$0
M01 · FY2002 · RR
STEM CELL BIOLOGY AND THERAPEUTICS CENTER$1,250,000
C06 · FY2001 · RR
CELLULAR PATHOGENESIS OF PEDIATRIC LIVER DISEASE$520,760
P01 · FY2001 · DK
Liver Injury in Alpha-1-Antitrypsin Deficiency$244,892
R01 · FY2001 · DK
LOCAL EXPRESSION OF ALPHA-1-ANTITRYPSIN IN EMPHYSEMA$238,000
R01 · FY2001 · HL
Iminosugars for treatment of antitrypsin deficiency$223,864
R41 · FY2001 · DK
Core--Cell biology$180,000
P30 · FY2001 · DK
ER RETENTION IN ALPHA-1-ANTITRYPSIN-LIVER DISEASE$175,576
P01 · FY2001 · DK
ER RETENTION IN ALPHA-1-ANTITRYPSIN LIVER DISEASE$130,161
R01 · FY2001 · DK
LOCAL EXPRESSION OF ALPHA-1-ANTITRYPSIN IN EMPHYSEMA$70,334
R01 · FY2001 · HL
LIVER INJURY IN ALPHA 1 ANTITRYPSIN DEFICIENCY$15,600
R01 · FY2001 · DK
ALPHA 1 ANTITRYPSIN DEFICIENCY--GENOTYPE/PHENOTYPE STUDIES$0
M01 · FY2001 · RR
CELLULAR PATHOGENESIS OF PEDIATRIC LIVER DISEASE$1,053,455
P01 · FY2000 · DK
LOCAL EXPRESSION OF ALPHA-1-ANTITRYPSIN IN EMPHYSEMA$348,750
R01 · FY2000 · HL
LIVER INJURY IN ALPHA 1 ANTITRYPSIN DEFICIENCY$252,903
R01 · FY2000 · DK
Core--Cell biology$180,000
P30 · FY2000 · DK
ER RETENTION IN ALPHA-1-ANTITRYPSIN-LIVER DISEASE$175,576
P01 · FY2000 · DK
PEDIATRIC GASTROENTEROLOGY RESEARCH TRAINING$142,642
T32 · FY2000 · HD
BILIARY ATRESIA IN THE INV MOUSE$80,824
R03 · FY2000 · DK
ALPHA 1 ANTITRYPSIN DEFICIENCY--GENOTYPE/PHENOTYPE STUDIES$0
M01 · FY2000 · RR